Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENHANCE
2024-518633-28-00Phase 2Authorised
- Sponsor
- Medical University of Vienna
- Start
- Oct 2022
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, single-arm trial of fexofenadine and pembrolizumab in non-small cell lung cancer (NSCLC), sponsored by Medical University of Vienna. Primary endpoint: Objective response rate according to RECIST 1.1 (ORR). Planned start Oct 2022; status: authorised.
02
Drugs
fexofenadinepembrolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2024-518633-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518633-28-00.